TABLE 2.
Severe in‐hospital outcomes among adults admitted to hospital with COVID‐19 during September 8, 2022–August 31, 2023, by vaccination status. Values are numbers (percentages) of total.
| Clinical outcome | No. with outcome/total | No. unvaccinated with outcome/total unvaccinated | No. original monovalent only with outcome/total original monovalent only | No. bivalent 7–89 days earlier with outcome/total bivalent 7–89 days earlier | No. bivalent 90–179 days earlier with outcome/total bivalent 90–179 days earlier |
|---|---|---|---|---|---|
| Supplemental oxygen therapy a | 1775/2918 (60.8) | 406/658 (61.7) | 1086/1807 (60.1) | 120/184 (65.2) | 163/269 (60.6) |
| Advanced respiratory support b | 568/2918 (19.5) | 159/658 (24.2) | 323/1807 (17.9) | 34/184 (18.5) | 52/269 (19.3) |
| Acute organ failure c | 632/2924 (21.6) | 168/660 (25.5) | 371/1811 (20.8) | 39/184 (21.2) | 54/269 (20.1) |
| ICU admission | 514/2924 (17.8) | 153/660 (23.2) | 281/1811 (15.5) | 38/184 (20.7) | 42/269 (15.6) |
| IMV or death | 281/2924 (9.6) | 92/660 (13.9) | 141/1811 (7.8) | 25/184 (13.4) | 23/269 (8.6) |
Abbreviations: ICU = intensive care unit, IMV = invasive mechanical ventilation.
Supplemental oxygen therapy was defined as any receipt of supplemental oxygen for patients with no chronic oxygen needs or escalation of respiratory support for patients on chronic oxygen at baseline. Patients on home IMV were not eligible for this outcome.
Advanced respiratory support was defined as new receipt of high‐flow nasal cannula, non‐invasive ventilation, or IMV. Patients on home IMV were not eligible for this outcome.
Acute organ failure was defined as respiratory failure (new receipt of high‐flow nasal cannula, noninvasive ventilation, or IMV), cardiovascular failure (receipt of vasopressors), or renal failure (new receipt of renal replacement therapy).